patients knew that they received botulinum toxin type A. This is called the open-label
phase.
For details on the results reported after Week 12 until the end of the study, see the
scientific results summary (a link to the summary is provided at the end of this
document).
Which patients were included in this study?
Studies have a list of requirements for patients who can enrol (inclusion criteria) and
those who can’t (exclusion criteria). For this study, the main inclusion and exclusion
criteria are listed below.
Men and women with urinary incontinence due to NDO were included in
the study if they:
• Were at least 20 years old.
• Had symptoms due to spinal cord injury or multiple sclerosis (a
condition that affects brain and spinal cord), for at least three
months before starting the study.
• Had symptoms that were not well controlled with their regular
medicine(s).
• Had frequent urinary incontinence episodes before starting the
treatment.
• Were using or agreed to have a thin, plastic tube inserted through
the urethra (catheterisation) to empty the bladder of urine, if
needed.